Early-stage Neuromodulation Target clinics and hospitals focused on chronic pain management and neuromodulation therapies, highlighting Neuronoff's Injectrode platform as a minimally invasive alternative to surgery and opioids to expand treatment options.

Animal to Human Translation Capitalize on recent large animal demonstration of the IPG-compatible Injectrode platform to approach contract research organizations, veterinary-nerve stimulation programs, and clinical trial sites seeking robust, remotely controllable neuromodulation capabilities.

Strategic Funding Momentum Leverage recent $4.5M funding and historical NIH grant support to engage potential investors, grant-funded programs, and strategic partners for scale-up, regulatory pathways, and partnership opportunities.

Modality Synergy Position Injectrode as a complement or alternative to existing peripheral nerve stimulation devices from larger competitors, emphasizing compatibility with standard IPG systems and connectors to simplify adoption for customers with existing infrastructure.

Market Positioning Highlight the focus on chronic pain, minimal invasiveness, and non-opioid therapy to engage healthcare systems and payer networks seeking value-based solutions and reduced opioid dependency.